Information  X 
Enter a valid email address

AstraZeneca PLC (AZN)

  Print      Mail a friend       Annual reports

Thursday 07 January, 2010

AstraZeneca PLC

AZ agreement with Teva on US

RNS Number : 1576F
AstraZeneca PLC
07 January 2010


AstraZeneca announced today that it has entered into an agreement with Teva Pharmaceutical Industries Ltd. and affiliates (collectively "Teva") to settle patent litigation regarding Teva's proposed generic version of AstraZeneca's Nexium delayed-release capsules (esomeprazole magnesium).  

As part of the Nexium settlement agreement, AstraZeneca has granted Teva a license to enter the US market with its generic esomeprazole on 27 May 2014, subject to regulatory approval, or earlier in certain circumstances. Teva has conceded that all patents-at-issue in Teva's US Nexium patent litigations are valid and enforceable. Teva has also conceded that six Nexium patents would be infringed by the manufacture or sale of Teva's US generic esomeprazole. The US District Court for the District of New Jersey will enter a Consent Judgment and corresponding Nexium patent litigations will be dismissed.

In a separate agreement, AstraZeneca and Teva have agreed to settle patent litigation related to Prilosec (omeprazole). Under this agreement, Teva will make a one-time payment to AstraZeneca for past infringing sales. The terms of this agreement are not financially material to AstraZeneca. AstraZeneca and Teva will jointly file a Stipulation of Dismissal with the US District Court for the Southern District of New York.  

Merck Sharp & Dohme Corp. (formerly Merck & Co., Inc.) ("Merck"), through KBI Inc. and KBI-E, and under the terms of Merck's restructured partnership with AstraZeneca, announced in 1998, also entered into the settlement agreements.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit:

Media Enquiries UK:

Neil McCrae

+44 20 7304 5045 (24 hours)

Chris Sampson

+44 20 7304 5130 (24 hours)

Sarah Lindgreen

+44 20 7304 5033 (24 hours)

Abigail Baron

+44 20 7304 5034 (24 hours)

Investor Enquiries UK:

Jonathan Hunt    

+44 207 304 5087

mob: +44 7775 704032

Karl Hård

+44 207 304 5322

mob: +44 7789 654364

Clive Morris

+44 207 304 5084

mob: +44 7710 031012

Investor Enquiries US:

Ed Seage

+1 302 886 4065

mob: +1 302 373 1361

Jorgen Winroth

+1 212 579 0506

mob: +1 917 612 4043

January 2010

- ENDS -

This information is provided by RNS
The company news service from the London Stock Exchange